Skip to main content
SpringerLink
Log in

Psoriasisarthritis – eine bleibende Herausforderung für Rheumatologen und Patienten

Teil 2: Bildgebende Diagnostik, Klassifikation, Therapie

Psoriatric arthritis – a permanent challenge for rheumatologists and patients

Part 2: Imaging diagnostics, classification and therapy

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

In den vergangenen Jahren wurde mithilfe einer Vielzahl verschiedener bildgebender Verfahren versucht, den Beginn sowie das Fortschreiten von arthritischen Veränderungen im Rahmen einer Psoriasisarthritis (PsA) zu dokumentieren. Zudem hat sich mit der Entdeckung neuer immunologischer Mechanismen das zur Verfügung stehende Therapierepertoire bei PsA grundlegend verbessert, wodurch sich die Wahrscheinlichkeit einer effektiven Behandlung für die Betroffenen merklich erhöht hat. Trotz eines nach wie vor fehlenden umfassenden Werts zur Angabe der gegenwärtigen Krankheitsaktivität steht inzwischen eine Reihe symptombezogener Instrumente zur Verfügung, um auch den Krankheitsverlauf und den damit verbundenen Behandlungserfolg dokumentieren zu können.

Abstract

In recent years a considerable number of imaging techniques have been used to demonstrate the onset and progression of arthritis-related changes in psoriatric arthritis (PsA). Moreover the identification of new immunological pathways has resulted in a substantial improvement of available therapies for PsA increasing the chance for the individual to receive effective treatment. Although an all-embracing disease activity score is still lacking, there is a variety of symptom-related tools to adequately reflect the course of disease and to evaluate the corresponding treatment success. This manuscript aims to give an overview of the latest corresponding knowledge with respect to PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Wassenberg S, Fischer-Kahle V, Herborn G, Rau R (2001) A method to score radiographic change in psoriatic arthritis. Z Rheumatol 60(3):156–166

    PubMed  CAS  Google Scholar 

  2. Gold RH, Bassett LW, Seeger LL (1988) The other arthritides. Roentgenologic features of osteoarthritis, erosive osteoarthritis, ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, multicentric reticulohistiocytosis, and progressive systemic sclerosis. Radiol Clin North Am 26(6):1195–1212

    PubMed  CAS  Google Scholar 

  3. Resnick D, Broderick TW (1977) Bony proliferation of terminal toe phalanges in psoriasis: the „ivory“ phalanx. J Can Assoc Radiol 28(3):187–189

    PubMed  CAS  Google Scholar 

  4. Rahman P, Nguyen E, Cheung C et al (2001) Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 28(5):1041–1044

    PubMed  CAS  Google Scholar 

  5. Salvarani C, Macchioni P, Cremonesi T et al (1992) The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study. Ann Rheum Dis 51(1):73–77

    PubMed  CAS  Google Scholar 

  6. Laiho K, Kauppi M (2002) The cervical spine in patients with psoriatic arthritis. Ann Rheum Dis 61(7):650–652

    PubMed  CAS  Google Scholar 

  7. Gladman DD, Shuckett R, Russell ML et al (1987) Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med 62(238):127–141

    PubMed  CAS  Google Scholar 

  8. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM et al (1991) Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 30(4):245–250

    Google Scholar 

  9. Taccari E, Spadaro A, Riccieri V (1996) Correlations between peripheral and axial radiological changes in patients with psoriatic polyarthritis. Rev Rhum Engl Ed 63(1):17–23

    PubMed  CAS  Google Scholar 

  10. Swen WA, Jacobs JW, Algra PR et al (1999) Sonography and magnetic resonance imaging equivalent for the assessment of full-thickness rotator cuff tears. Arthritis Rheum 42(10):2231–2238

    PubMed  CAS  Google Scholar 

  11. Wakefield RJ, Gibbon WW, Conaghan PG et al (2000) The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 43(12):2762–2770

    PubMed  CAS  Google Scholar 

  12. D’Agostino MA, Said-Nahal R, Hacquard-Bouder C et al (2003) Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 48(2):523–533

    Google Scholar 

  13. De Simone C, Guerriero C, Giampetruzzi AR et al (2003) Achilles tendinitis in psoriasis: clinical and sonographic findings. J Am Acad Dermatol 49(2):217–222

    Google Scholar 

  14. Falsetti P, Frediani B, Fioravanti A et al (2003) Sonographic study of calcaneal entheses in erosive osteoarthritis, nodal osteoarthritis, rheumatoid arthritis and psoriatic arthritis. Scand J Rheumatol 32(4):229–234

    PubMed  CAS  Google Scholar 

  15. Hu Y, Zhu J, Xue Q et al (2011) Scanning of the sacroiliac joint and entheses by color doppler ultrasonography in patients with ankylosing spondylitis. J Rheumatol 38(8):1651–1655

    PubMed  Google Scholar 

  16. Hartung W, Ross CJ, Straub R et al (2010) Ultrasound-guided sacroiliac joint injection in patients with established sacroiliitis: precise IA injection verified by MRI scanning does not predict clinical outcome. Rheumatology (Oxford) 49(8):1479–1482

    Google Scholar 

  17. McQueen FM, Benton N, Crabbe J et al (2001) What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 60(9):859–868

    PubMed  CAS  Google Scholar 

  18. Antoni C, Dechant C, Hanns-Martin Lorenz PD et al (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47(5):506–512

    PubMed  CAS  Google Scholar 

  19. Ostergaard M, Peterfy C, Conaghan P et al (2003) OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30(6):1385–1386

    PubMed  Google Scholar 

  20. Ostergaard M, McQueen F, Wiell C et al (2009) The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands. J Rheumatol 36(8):1816–1824

    PubMed  Google Scholar 

  21. Grigoryan M, Roemer FW, Mohr A, Genant HK (2004) Imaging in spondyloarthropathies. Curr Rheumatol Rep 6(2):102–109

    PubMed  Google Scholar 

  22. Puhakka KB, Jurik AG, Egund N et al (2003) Imaging of sacroiliitis in early seronegative spondylarthropathy. Assessment of abnormalities by MR in comparison with radiography and CT. Acta Radiol 44(2):218–229

    PubMed  Google Scholar 

  23. Mehta NN, Yu Y, Saboury B et al (2011) Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol

  24. Finzel S, Englbrecht M, Engelke K et al (2011) A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 70(1):122–127

    PubMed  Google Scholar 

  25. Gladman DD (2008) Mortality in psoriatic arthritis. Clin Exp Rheumatol 26(5 Suppl 51):62–65

    Google Scholar 

  26. Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673

    PubMed  Google Scholar 

  27. Congi L, Roussou E (2010) Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol 28(3):304–310

    PubMed  Google Scholar 

  28. Schnarr S (2006) Arthritis psoriatica. In: Kuipers J, Zeidler H, Köhler L (Hrsg) Medal Rheumatologie. Wiskom, Friedrichshafen, S 58

  29. McGonagle D, Conaghan PG, Emery P (1999) Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 42(6):1080–1086

    PubMed  CAS  Google Scholar 

  30. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55–78

    PubMed  CAS  Google Scholar 

  31. Vasey F, Espinoza L (1984) Psoriatic arthropathy. In: Calin A (Hrsg) Spondyloarthropathies. Grune & Stratton, Orlando, FL, S 151–185

  32. Bennett RM (1979) Psoriatic arthritis. In: McCarty DJ (Hrsg) Arthritis and allied conditions, 9. Aufl. Lea & Febiger, Philadelphia, S 645

  33. Härle P, Hartung W, Lehmann P et al (2010) Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting. Z Rheumatol 69(2):157–160, 62–63

    PubMed  Google Scholar 

  34. Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii65–ii68; discussion ii9–ii73

    PubMed  Google Scholar 

  35. Rich P, Scher RK (2003) Nail Psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 49(2):206–212

    PubMed  Google Scholar 

  36. Cassell SE, Bieber JD, Rich P et al (2007) The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 34(1):123–129

    PubMed  Google Scholar 

  37. Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 59(5):686–691

    PubMed  Google Scholar 

  38. Heuft-Dorenbosch L, Spoorenberg A, Tubergen A van et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132

    PubMed  CAS  Google Scholar 

  39. Felson DT, Anderson JJ, Boers M et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical trials. Arthritis Rheum 36(6):729–740

    PubMed  CAS  Google Scholar 

  40. Helliwell PS, Firth J, Ibrahim GH et al (2005) Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 32(9):1745–1750

    PubMed  Google Scholar 

  41. Jones SD, Porter J, Garrett SL et al (1995) A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 22(8):1609

    PubMed  CAS  Google Scholar 

  42. Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285

    PubMed  CAS  Google Scholar 

  43. Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 9(5):789–793

    PubMed  CAS  Google Scholar 

  44. Chandran V, Bhella S, Schentag C, Gladman DD (2007) Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 66(7):936–939

    PubMed  Google Scholar 

  45. Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291

    PubMed  CAS  Google Scholar 

  46. Englbrecht M, Wang Y, Ronneberger M et al (2010) Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. Arthritis Care Res (Hoboken) 62(7):977–983

    Google Scholar 

  47. Khan M, Schentag C, Gladman DD (2003) Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 30(5):1022–1026

    PubMed  Google Scholar 

  48. Radtke MA, Reich K, Blome C et al (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691

    PubMed  CAS  Google Scholar 

  49. Christophers E, Barker JN, Griffiths CE et al (2010) The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 24(5):548–554

    PubMed  CAS  Google Scholar 

  50. Love TJ, Gudjonsson JE, Valdimarsson H, Gudbjornsson B (2010) Small joint involvement in psoriatic arthritis is associated with onycholysis: the Reykjavik Psoriatic Arthritis Study. Scand J Rheumatol 39(4):299–302

    PubMed  CAS  Google Scholar 

  51. Williamson L, Dalbeth N, Dockerty JL et al (2004) Extended report: nail disease in psoriatic arthritis – clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 43(6):790–794

    Google Scholar 

  52. McGonagle D (2009) Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 23(Suppl 1):9–13

    PubMed  CAS  Google Scholar 

  53. Gladman DD, Stafford-Brady F, Chang CH et al (1990) Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 17(6):809–812

    PubMed  CAS  Google Scholar 

  54. Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42(12):1460–1468

    Google Scholar 

  55. Gladman DD (1994) Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 8(2):379–394

    PubMed  CAS  Google Scholar 

  56. Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41(6):1103–1110

    PubMed  CAS  Google Scholar 

  57. Bond SJ, Farewell VT, Schentag CT, Gladman DD (2007) Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 66(3):370–376

    PubMed  Google Scholar 

  58. Husted JA, Tom BD, Farewell VT et al (2005) Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum 53(3):404–409

    PubMed  Google Scholar 

  59. Gladman DD, Farewell VT, Kopciuk KA, Cook RJ (1998) HLA markers and progression in psoriatic arthritis. J Rheumatol 25(4):730–733

    PubMed  CAS  Google Scholar 

  60. Gladman DD, Farewell VT (1999) Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 26(11):2409–2413

    PubMed  CAS  Google Scholar 

  61. Gladman DD, Farewell VT, Nadeau C (1995) Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 22(4):675–679

    PubMed  CAS  Google Scholar 

  62. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I (2003) A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 62(1):68–70

    PubMed  CAS  Google Scholar 

  63. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66(Suppl 3):iii56–iii60

    PubMed  Google Scholar 

  64. Vlam K de, Lories RJ (2008) Remission in psoriatic arthritis. Curr Rheumatol Rep 10(4):297–302

    PubMed  Google Scholar 

  65. Ritchlin CT, Kavanaugh A, Gladman DD et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387–1394

    PubMed  CAS  Google Scholar 

  66. Kavanaugh AF, Ritchlin CT (2006) Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 33(7):1417–1421

    PubMed  Google Scholar 

  67. Soriano ER, McHugh NJ (2006) Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 33(7):1422–1430

    PubMed  Google Scholar 

  68. Nash P (2006) Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 33(7):1431–1434

    PubMed  Google Scholar 

  69. Ritchlin CT (2006) Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 33(7):1435–1438

    PubMed  Google Scholar 

  70. Strober BE, Siu K, Menon K (2006) Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 33(7):1442–1446

    PubMed  Google Scholar 

  71. Boehncke WH, Prinz J, Gottlieb AB (2006) Biologic therapies for psoriasis. A systematic review. J Rheumatol 33(7):1447–1451

    PubMed  Google Scholar 

  72. Cassell S, Kavanaugh AF (2006) Therapies for psoriatic nail disease. A systematic review. J Rheumatol 33(7):1452–1456

    PubMed  CAS  Google Scholar 

  73. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53

    PubMed  CAS  Google Scholar 

  74. Coates LC, Cook R, Lee KA et al (2010) Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 62(7):970–976

    Google Scholar 

  75. Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62(7):965–969

    Google Scholar 

  76. Sarzi-Puttini P, Santandrea S, Boccassini L et al (2001) The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 19(1 Suppl 22):17–20

    Google Scholar 

  77. Clark DW, Coulter DM (2003) Psoriasis associated with rofecoxib. Arch Dermatol 139(9):1223

    PubMed  Google Scholar 

  78. Nash P, Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64(Suppl 2):ii74–ii77

    PubMed  CAS  Google Scholar 

  79. Mease PJ (2009) Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 21(4):348–355

    PubMed  Google Scholar 

  80. Black RL, O’Brien WM, Vanscott EJ et al (1964) Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 189:743–747

    PubMed  CAS  Google Scholar 

  81. Abu-Shakra M, Gladman DD, Thorne JC et al (1995) Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22(2):241–245

    PubMed  CAS  Google Scholar 

  82. St Clair EW (2002) Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 61(Suppl 2):ii67–ii69

    Google Scholar 

  83. Combe B, Goupille P, Kuntz JL et al (1996) Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 35(7):664–668

    PubMed  CAS  Google Scholar 

  84. Rahman P, Gladman DD, Cook RJ et al (1998) The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 25(10):1957–1961

    PubMed  CAS  Google Scholar 

  85. Clegg DO, Reda DJ, Mejias E et al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39(12):2013–2020

    PubMed  CAS  Google Scholar 

  86. Farr M, Kitas GD, Waterhouse L et al (1990) Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 29(1):46–49

    PubMed  CAS  Google Scholar 

  87. Gupta AK, Grober JS, Hamilton TA et al (1995) Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 22(5):894–898

    PubMed  CAS  Google Scholar 

  88. Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42(11):2325–2329

    PubMed  CAS  Google Scholar 

  89. Fraser SM, Hopkins R, Hunter JA et al (1993) Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 32(10):923–925

    PubMed  CAS  Google Scholar 

  90. Dougados M, Linden S vam der, Leirisalo-Repo M et al (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38(5):618–627

    PubMed  CAS  Google Scholar 

  91. Fox RI (1998) Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 53:20–26

    PubMed  CAS  Google Scholar 

  92. Liang GC, Barr WG (2001) Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 7(6):366–370

    PubMed  CAS  Google Scholar 

  93. Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50(6):1939–1950

    PubMed  CAS  Google Scholar 

  94. Steinsson K, Jonsdottir I, Valdimarsson H (1990) Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 49(8):603–606

    PubMed  CAS  Google Scholar 

  95. Spadaro A, Riccieri V, Sili-Scavalli A et al (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13(5):589–593

    PubMed  CAS  Google Scholar 

  96. Mazzanti G, Coloni L, De Sabbata G, Paladini G (1994) Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh) 186:116–117

    Google Scholar 

  97. Gladman DD, Blake R, Brubacher B, Farewell VT (1992) Chloroquine therapy in psoriatic arthritis. J Rheumatol 19(11):1724–1726

    PubMed  CAS  Google Scholar 

  98. Lipsky JJ (1996) Mycophenolate mofetil. Lancet 348(9038):1357–1359

    PubMed  CAS  Google Scholar 

  99. Grundmann-Kollmann M, Mooser G, Schraeder P et al (2000) Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 42(5 Pt 1):835–837

    PubMed  CAS  Google Scholar 

  100. Baum J, Hurd E, Lewis D et al (1973) Treatment of psoriatic arthritis with 6-mercaptopurine. Arthritis Rheum 16(2):139–147

    PubMed  CAS  Google Scholar 

  101. Wahba A, Cohen H (1980) Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol 60(6):515–520

    PubMed  CAS  Google Scholar 

  102. Seideman P, Fjellner B, Johannesson A (1987) Psoriatic arthritis treated with oral colchicine. J Rheumatol 14(4):777–779

    PubMed  CAS  Google Scholar 

  103. Price R, Gibson T (1986) D-penicillamine and psoriatic arthropathy. Br J Rheumatol 25(2):228

    PubMed  CAS  Google Scholar 

  104. Jung N, Hellmann M, Hoheisel R et al (2010) An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 29(10):1169–1173

    PubMed  Google Scholar 

  105. Sterry W, Ortonne JP, Kirkham B et al (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340:c147

    PubMed  Google Scholar 

  106. Antoni C, Krueger GG, Vlam K de et al (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157

    PubMed  CAS  Google Scholar 

  107. Mease PJ, Gladman DD, Ritchlin CT et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289

    PubMed  CAS  Google Scholar 

  108. Kavanaugh A, McInnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976–986

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Die Autoren weisen auf folgende Beziehungen hin: Referententätigkeit für die Unternehmen Roche, Pfizer (ehemals Wyeth), Abbott, Novaris, UCB (M.E.); Roche, Abbott (Vertragshonorare; S.F.).

Author information

Authors and Affiliations

  1. Medizinische Klinik III (Rheumatologie & Immunologie), Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland

    S. Finzel & M. Englbrecht

Authors
  1. S. Finzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Englbrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to S. Finzel or M. Englbrecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finzel, S., Englbrecht, M. Psoriasisarthritis – eine bleibende Herausforderung für Rheumatologen und Patienten. Z. Rheumatol. 70, 775–789 (2011). https://doi.org/10.1007/s00393-011-0870-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-011-0870-y

Schlüsselwörter

Keywords

Search

Navigation